Cargando…

The systolic paradox in hypertrophic cardiomyopathy

OBJECTIVE: We explored cardiac volumes and the effects on systolic function in hypertrophic cardiomyopathy (HCM) patients with left ventricular hypertrophy (HCM LVH+) and genotype-positive patients without left ventricular hypertrophy (HCM LVH−). METHODS: We included 180 HCM LVH+, 100 HCM LVH− patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Haland, Trine F, Hasselberg, Nina E, Almaas, Vibeke Marie, Dejgaard, Lars A, Saberniak, Jørg, Leren, Ida S, Berge, Knut Erik, Haugaa, Kristina H, Edvardsen, Thor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Open Heart 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471858/
https://www.ncbi.nlm.nih.gov/pubmed/28674623
http://dx.doi.org/10.1136/openhrt-2016-000571
_version_ 1783244030269718528
author Haland, Trine F
Hasselberg, Nina E
Almaas, Vibeke Marie
Dejgaard, Lars A
Saberniak, Jørg
Leren, Ida S
Berge, Knut Erik
Haugaa, Kristina H
Edvardsen, Thor
author_facet Haland, Trine F
Hasselberg, Nina E
Almaas, Vibeke Marie
Dejgaard, Lars A
Saberniak, Jørg
Leren, Ida S
Berge, Knut Erik
Haugaa, Kristina H
Edvardsen, Thor
author_sort Haland, Trine F
collection PubMed
description OBJECTIVE: We explored cardiac volumes and the effects on systolic function in hypertrophic cardiomyopathy (HCM) patients with left ventricular hypertrophy (HCM LVH+) and genotype-positive patients without left ventricular hypertrophy (HCM LVH−). METHODS: We included 180 HCM LVH+, 100 HCM LVH− patients and 80 healthy individuals. End-Diastolic Volume Index (EDVI), End-Systolic Volume Index (ESVI) and ejection fraction (EF) were assessed by echocardiography. Left ventricular (LV) global longitudinal strain (GLS) was measured by speckle tracking echocardiography. RESULTS: EDVI and ESVI were significantly smaller in HCM LVH+ compared with HCM LVH− patients (41±14 mL/m(2) vs 49±13 mL/m(2) and 16±7 mL/m(2) vs 19±6 mL/m(2), respectively, both p<0.001) and in healthy individuals (41±14 mL/m(2) vs 57±14 mL/m(2) and 16±7 mL/m(2) vs 23±9 mL/m(2), respectively, both p<0.001). HCM LVH− patients had significantly lower EDVI and ESVI compared with healthy individuals (49±13 mL/m(2) vs 57±14 mL/m(2) and 19±6 mL/m(2) vs 23±9 mL/m(2), both p<0.001). EF was similar (61%±7% vs 60%±8% vs 61%±6%, p=0.43) in the HCM LVH+, HCM LVH– and healthy individuals, despite significantly worse GLS in the HCM LVH+ (−16.4%±3.7% vs −21.3%±2.4% vs −22.3%±3.7%, p<0.001). GLS was worse in the HCM LVH− compared with healthy individuals in pairwise comparison (p=0.001). Decrease in ESVI was closely related to EF in HCM LVH+ and HCM LVH− (R=0.45, p<0.001 and R=0.43, p<0.001) as expected, but there was no relationship with GLS (R=0.02, p=0.77 and R=0.11, p=0.31). Increased maximal wall thickness (MWT) correlated significantly with worse GLS (R=0.58, p<0.001), but not with EF (R=0.018, p=0.30) in the HCM LVH+ patients. CONCLUSION: HCM LVH+ had smaller cardiac volumes that could explain the preserved EF, despite worse GLS that was closely related to MWT. HCM LVH− had reduced cardiac volumes and subtle changes in GLS compared with healthy individuals, indicating a continuum of both volumetric and systolic changes present before increased MWT.
format Online
Article
Text
id pubmed-5471858
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Open Heart
record_format MEDLINE/PubMed
spelling pubmed-54718582017-07-03 The systolic paradox in hypertrophic cardiomyopathy Haland, Trine F Hasselberg, Nina E Almaas, Vibeke Marie Dejgaard, Lars A Saberniak, Jørg Leren, Ida S Berge, Knut Erik Haugaa, Kristina H Edvardsen, Thor Open Heart Heart and Cardiomyopathies OBJECTIVE: We explored cardiac volumes and the effects on systolic function in hypertrophic cardiomyopathy (HCM) patients with left ventricular hypertrophy (HCM LVH+) and genotype-positive patients without left ventricular hypertrophy (HCM LVH−). METHODS: We included 180 HCM LVH+, 100 HCM LVH− patients and 80 healthy individuals. End-Diastolic Volume Index (EDVI), End-Systolic Volume Index (ESVI) and ejection fraction (EF) were assessed by echocardiography. Left ventricular (LV) global longitudinal strain (GLS) was measured by speckle tracking echocardiography. RESULTS: EDVI and ESVI were significantly smaller in HCM LVH+ compared with HCM LVH− patients (41±14 mL/m(2) vs 49±13 mL/m(2) and 16±7 mL/m(2) vs 19±6 mL/m(2), respectively, both p<0.001) and in healthy individuals (41±14 mL/m(2) vs 57±14 mL/m(2) and 16±7 mL/m(2) vs 23±9 mL/m(2), respectively, both p<0.001). HCM LVH− patients had significantly lower EDVI and ESVI compared with healthy individuals (49±13 mL/m(2) vs 57±14 mL/m(2) and 19±6 mL/m(2) vs 23±9 mL/m(2), both p<0.001). EF was similar (61%±7% vs 60%±8% vs 61%±6%, p=0.43) in the HCM LVH+, HCM LVH– and healthy individuals, despite significantly worse GLS in the HCM LVH+ (−16.4%±3.7% vs −21.3%±2.4% vs −22.3%±3.7%, p<0.001). GLS was worse in the HCM LVH− compared with healthy individuals in pairwise comparison (p=0.001). Decrease in ESVI was closely related to EF in HCM LVH+ and HCM LVH− (R=0.45, p<0.001 and R=0.43, p<0.001) as expected, but there was no relationship with GLS (R=0.02, p=0.77 and R=0.11, p=0.31). Increased maximal wall thickness (MWT) correlated significantly with worse GLS (R=0.58, p<0.001), but not with EF (R=0.018, p=0.30) in the HCM LVH+ patients. CONCLUSION: HCM LVH+ had smaller cardiac volumes that could explain the preserved EF, despite worse GLS that was closely related to MWT. HCM LVH− had reduced cardiac volumes and subtle changes in GLS compared with healthy individuals, indicating a continuum of both volumetric and systolic changes present before increased MWT. Open Heart 2017-05-16 /pmc/articles/PMC5471858/ /pubmed/28674623 http://dx.doi.org/10.1136/openhrt-2016-000571 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Heart and Cardiomyopathies
Haland, Trine F
Hasselberg, Nina E
Almaas, Vibeke Marie
Dejgaard, Lars A
Saberniak, Jørg
Leren, Ida S
Berge, Knut Erik
Haugaa, Kristina H
Edvardsen, Thor
The systolic paradox in hypertrophic cardiomyopathy
title The systolic paradox in hypertrophic cardiomyopathy
title_full The systolic paradox in hypertrophic cardiomyopathy
title_fullStr The systolic paradox in hypertrophic cardiomyopathy
title_full_unstemmed The systolic paradox in hypertrophic cardiomyopathy
title_short The systolic paradox in hypertrophic cardiomyopathy
title_sort systolic paradox in hypertrophic cardiomyopathy
topic Heart and Cardiomyopathies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471858/
https://www.ncbi.nlm.nih.gov/pubmed/28674623
http://dx.doi.org/10.1136/openhrt-2016-000571
work_keys_str_mv AT halandtrinef thesystolicparadoxinhypertrophiccardiomyopathy
AT hasselbergninae thesystolicparadoxinhypertrophiccardiomyopathy
AT almaasvibekemarie thesystolicparadoxinhypertrophiccardiomyopathy
AT dejgaardlarsa thesystolicparadoxinhypertrophiccardiomyopathy
AT saberniakjørg thesystolicparadoxinhypertrophiccardiomyopathy
AT lerenidas thesystolicparadoxinhypertrophiccardiomyopathy
AT bergeknuterik thesystolicparadoxinhypertrophiccardiomyopathy
AT haugaakristinah thesystolicparadoxinhypertrophiccardiomyopathy
AT edvardsenthor thesystolicparadoxinhypertrophiccardiomyopathy
AT halandtrinef systolicparadoxinhypertrophiccardiomyopathy
AT hasselbergninae systolicparadoxinhypertrophiccardiomyopathy
AT almaasvibekemarie systolicparadoxinhypertrophiccardiomyopathy
AT dejgaardlarsa systolicparadoxinhypertrophiccardiomyopathy
AT saberniakjørg systolicparadoxinhypertrophiccardiomyopathy
AT lerenidas systolicparadoxinhypertrophiccardiomyopathy
AT bergeknuterik systolicparadoxinhypertrophiccardiomyopathy
AT haugaakristinah systolicparadoxinhypertrophiccardiomyopathy
AT edvardsenthor systolicparadoxinhypertrophiccardiomyopathy